These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21740074)

  • 1. Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.
    Van den Bergh A; Sinha V; Gilissen R; Straetemans R; Wuyts K; Morrison D; Bijnens L; Mackie C
    Clin Pharmacokinet; 2011 Aug; 50(8):505-17. PubMed ID: 21740074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
    Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
    Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel strategy for physiologically based predictions of human pharmacokinetics.
    Jones HM; Parrott N; Jorga K; Lavé T
    Clin Pharmacokinet; 2006; 45(5):511-42. PubMed ID: 16640456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.
    Berezhkovskiy LM
    J Pharm Sci; 2011 Jun; 100(6):2482-97. PubMed ID: 21254063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans--usefulness of exponent on prospective evaluation of predictability.
    Sayama H; Komura H; Kogayu M
    Drug Metab Dispos; 2013 Feb; 41(2):498-507. PubMed ID: 23209193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species differences in distribution and prediction of human V(ss) from preclinical data.
    Berry LM; Li C; Zhao Z
    Drug Metab Dispos; 2011 Nov; 39(11):2103-16. PubMed ID: 21852367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds.
    Fura A; Vyas V; Humphreys W; Chimalokonda A; Rodrigues D
    Biopharm Drug Dispos; 2008 Nov; 29(8):455-68. PubMed ID: 18989850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
    Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of volume of distribution at steady state in humans: comparison of different approaches.
    Zou P; Zheng N; Yang Y; Yu LX; Sun D
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):855-72. PubMed ID: 22591253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions.
    Mahmood I
    J Pharm Pharmacol; 1998 May; 50(5):493-9. PubMed ID: 9643442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
    Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
    J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting oral clearance in humans: how close can we get with allometry?
    Sinha VK; De Buck SS; Fenu LA; Smit JW; Nijsen M; Gilissen RA; Van Peer A; Lavrijsen K; Mackie CE
    Clin Pharmacokinet; 2008; 47(1):35-45. PubMed ID: 18076217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.
    Jones RD; Jones HM; Rowland M; Gibson CR; Yates JW; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4074-89. PubMed ID: 21452299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles.
    Wajima T; Yano Y; Fukumura K; Oguma T
    J Pharm Sci; 2004 Jul; 93(7):1890-900. PubMed ID: 15176076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.
    Zou P; Zheng N; Yu Y; Yu S; Sun W; McEachem D; Yang Y; Yu LX; Wang S; Sun D
    J Pharm Pharm Sci; 2012; 15(2):265-80. PubMed ID: 22579006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.
    Teitelbaum Z; Lave T; Freijer J; Cohen AF
    Clin Pharmacokinet; 2010 Sep; 49(9):619-32. PubMed ID: 20690784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.